title: Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
abstract: Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Müllerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation. The utility of AMH as a potential marker of chemotherapy-induced ovarian follicular depletion and an early plasma marker of chemotherapy-induced gonadal damage has been evaluated both in young women after treatment for cancer in childhood and in young survivors of hematological malignancies and solid tumors. Several studies have demonstrated a potential utility of AMH, inhibin, or follicle-stimulating factor as biomarkers predicting infertility risk in breast cancer patients, but the studies conducted so far are not conclusive. Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH.
authors.affiliation: Department of Oncology, University Hospital of Udine, Udine, Italy Department of Medical and Biological Sciences, University of Udine, Udine, Italy Department of Medical Oncology (UO Oncologia Medica A), IRCCS AOU San Martino-IST, Largo Rosanna Benzi, 10, 16132 Genova, Italy Department of Radiation Oncology, New York University School of Medicine, New York, New York, USA Mother and Child Department, Pordenone Hospital, Pordenone, Italy Department of Medical Oncology (SS Sviluppo Terapie Innovative), IRCCS AOU San Martino-IST, Genova, Italy.
authors.forename: Claudia
authors.initials: C
authors.lastname: Bozza
authors.forename: Fabio
authors.initials: F
authors.lastname: Puglisi
authors.forename: Matteo
authors.initials: M
authors.lastname: Lambertini
authors.forename: Etin-Osa
authors.initials: EO
authors.lastname: Osa
authors.forename: Massimo
authors.initials: M
authors.lastname: Manno
authors.forename: Lucia
authors.initials: L
authors.lastname: Del Mastro
mesh_terms: D054304:Anti-Mullerian Hormone / Q000097:blood*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007265:Inhibins / Q000097:blood; D006080:Ovarian Follicle / Q000503:physiopathology*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C422364:inhibin B; D004958:Estradiol; D007265:Inhibins; D054304:Anti-Mullerian Hormone; D005640:Follicle Stimulating Hormone
keywords: breast; growth factor; hormone action; oncology